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Abstract
The immune system and cancer coexist in close relationship which is an indispensable
part of the processes of tumorigenesis, tumor growth, and metastatic spread. The elu‐
cidation and understanding of this continuous process could provide opportunities to
develop strategies to impact the prognosis, and eventually to improve the cancer
treatment process. Such strategies have been already implicated and proven efficient
in the treatment of several tumor localizations such as malignant melanoma, lung and
renal cancer. The present publication reviews the principles of cancer-related immune
response, types and mechanisms of immune response and suppression, immunother‐
apy of solid tumors. We also discuss the pathways and the signaling molecules, par‐
ticipating in those immune response/suppression processes, turning them into
potential targets and their actual and potential future role in the management of solid
tumors. We focus on potential role and rationale for combination of immunothera‐
peutic and chemotherapeutic/targeted agents and radiotherapy in one treatment strat‐
egy.
Keywords: immune response, immune suppression, checkpoint inhibitors, immuno‐
therapy, solid tumors
1. Introduction
The relationship between the immune system and cancer has recently become a “modern
topic” of interest in cancer research even though it was back in the early 1800s, when Virchow
first described the presence of inflammatory cells in pathohistological tumor samples.
Subsequently, Coley demonstrated that the use of bacterial products induced certain regres‐
sion in inoperable tumors [1]. It has been known for decades that the immune system plays an
important role in the processes of inflammation, chronic inflammation, and cancer. Thus,
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scientific researchers continued the struggle to understand the role of Virchow’s findings,
aiming to link those processes. The elucidation of such relation could give an insight into the
processes of tumorigenesis, tumor growth, and metastatic spread; it could potentially provide
subsequent opportunities to develop strategies to impact the diagnosis, prognosis, and
eventually to improve the cancer treatment process. The synallagmatic reciprocal talk between
the host immune system and the tumor has been intensively studied. The processes of the host
immune control over the tumor, immunoediting by the tumor, the immune escape, and the
development of immune tolerance and suppression are described in this chapter. Our aim is
also 1) to highlight the principles of cancer-related immune mechanisms, immunotherapy, and
their role in the process of treatment of solid tumors; - and 2) to discuss the options to combine
immunotherapeutic and chemotherapeutic agents trying to overcome the mechanisms of
immune or inflammatory suppression and potentially improve cancer treatment strategies.
The initial immune-related therapies were aiming to activate the immune system and were
represented by non-specific immunotherapies that didn’t aim towards a specific target in the
cancer cell (cytokines, interleukins, interferons, etc.). Subsequent efforts tried to identify
antigens of the cancer cell and to design monoclonal antibodies (MAB), targeting those
antigens. However, it has become clear that these therapies are failing because of the ability of
cancers to induce immune tolerance, evasion, and suppression of the immune system, which
created a new direction of research - to discover the pathways and the signaling molecules,
participating in those immune suppression processes, thus turning them into potential targets
as anticancer treatments.
2. Basic principles of immune response
There has been major growth in the understanding of the immune role and its relationship to
cancer progression and therapy. The immune system comprises of a multitude of intercon‐
nected cells and tissues, distributed in the body. It basically consists of three general categories
of blood cells: 1) lymphocytes (T, B cells and natural killer (NK) cells); 2) myeloid cells
(macrophages, dendritic cells, and antigen presenting cells); and 3) granulocytes (neutrophils,
basophils, and eosinophils). Simplified, the immune system protects the organism from
harmful foreign agents (antigens) by producing specific proteins (antibodies). Those antibod‐
ies circulate until they find and attach to the targeted antigen, thus triggering immune response
and destruction of the antigen-containing cells.
2.1. Principles of immune response in solid tumors
The anti-cancer immune response could be largely divided into two types: innate and adaptive
immune response. The innate immunity includes the granulocytes, macrophages, dendritic
cells, mast cells, and NK cells serving as a first-line protective mechanism, recognizing stressed
mutating cells of the organism, and triggering effector mechanism, aiming their eradication.
Subsequently, the adaptive immune response is triggered - it consists of specific immune
activation of B cells, CD 4- and CD 8-expressing T-lymphocytes.
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2.1.1. Innate antitumor response
Normal cells of the organism could become subject of malignant genetic and epigenetic
transformation and thus acquire additional characteristics, permitting their uncontrolled
proliferation, survival, and dissemination. Such genetic injuries stimulate the innate immune
system, which normally serves as a front-line surveillance mechanism, reacting immediately.
The NK cells distinguish normal from tumor cells by a complex process of expression of
different inhibitory and stimulatory molecules. Specific MHC inhibitory receptors have been
described, shedding light over the molecular basis of the activation of the NK cell during the
process of natural cytotoxicity of the innate antitumor response. Different receptors frequently
referred to as natural cytotoxicity receptors (NCR) are expressed at the surface of the NK cell;
they comprise of molecules such as NKp46, NKp30, NKp44, and NKG2D, which bind to their
ligands of the MHC class I [2]. NKG2D appears to play either a complementary or a synergistic
role with NCRs. The expression of those ligands is induced on the surface of the stressed
transformed tumor cells [3,4]. The binding of the MHC-I related ligands to the NKG2D triggers
activation of NK cells, NKT and γδ T cells, and CD 8 T cells, which inhibit tumor cytotoxicity
and IFN-γ production. Extracellular release of cytoplasmic stress molecules, such as HSP-70,
HMGB1, and uric acid, activates macrophages and dendritic cells, resulting in IL-12 production
and transition to the adaptive immunity [5].
2.1.2. Adaptive antitumor responses
The adaptive immune response could be described as the “second-line” response. As a highly
specific response to a specific pathogen, it starts relatively later after the initial rapid innate
reaction. It is triggered by the dendritic cells, which capture, process, and present tumor
antigens to the class I and II MHC, thus stimulating the antigen-specific T- and B-lymphocytes
(cellular response) and the specific production of antibodies (humoral component).
Macrophages, dendritic cells, and antigen-presenting cells (APCs) recognize foreign cells and
participate in the immune response as they are one of the first responders, approaching a
potential harmful antigen. They internalize those extracellular antigens via phagocytosis or
receptor-mediated endocytosis; they process and fragment the proteins into peptide sequences
that are subsequently presented back at the extracellular membrane surface of the APCs within
the context of the Major Histocompatibility Complex (MHC) class II (Figure 1). They also
produce large amounts of different cytokines, thus promoting immune response. In cases of
inadequately directed immune reaction towards self-antigens, the dendritic cells particularly
prevent further autoimmune reaction [6]. In order to prevent self-destruction, the immune
system uses endogenous crosstalks—“immune checkpoints”—that normally terminate
immune responses after antigens activation of T-cells.
Once the immune response is triggered, the foreign antigen is presented to other cells of the
immune complex. More specialized cells, the lymphocytes, encounter the foreign antigen and
respond by proliferation and differentiation into different subpopulations. B-lymphocytes
arise and differentiate in the bone marrow and enter into the blood stream as functional mature
cells. They express a receptor for the antigen on their surface and following encounter with
that specific antigen, they start to divide, differentiate into plasma cells, and produce soluble
Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors
http://dx.doi.org/10.5772/61211
79
immunoglobulin molecules—antibodies in the circulation. T cells arise in the bone marrow
and migrate to the thymus (named thereafter) where they undergo a process of maturation.
Immunocompetent T cells leave the thymus and enter into the circulation. There are different
T cells classified by their function and phenotype. The largest part of T cells expresses CD 4
glycoprotein and are called T helpers. They enhance the immune process by secreting cyto‐
kines and direct cell-to-cell contact [7]. Other numerous specific functional T-lymphocytes are
called cytotoxic (CTLs). They express CD8 glycoprotein and are capable of direct killing of the
antigen-containing cells (virally infected or cancerous). Upon encounter of their target, they
kill it by induction of apoptosis in the infected or cancerous cell. A part of the lymphocytes
remain as sensitized long-living memory cells, recognizing only a single antigen, posed to
respond if it is encountered again. The regulatory T cells (T regs) are a small population of T
cells and express CD 25 glycoprotein, which participate in the process of self-antigen recog‐
Figure 1. Induction of rapid innate and retarded adaptive immune response (humoral and cellular T- and B-cell re‐
sponse). Tumor cell proteins are degraded into smaller peptides in endosomes/lysosomes in the APCs and are subse‐
quently expressed on the cell surface in MHC class II peptide complexes, which can be recognized by CD4+ T helper
lymphocyte cells. T helpers assist B cells to proliferate and mature into antibody-producing plasma cells. Via this route
of antigen acquisition, DCs can also present epitopes to CD8+ T cells. This is also known as cross-presentation.
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nition, preventing autoimmune reactions [8, 9]. If the immune system functions correctly, its
work remains unnoticed, efficiently protecting the individual from a variety of foreign
pathogens. In cases of dysfunction, however, severe consequences appear, presented either as
immunodeficiency or autoimmunity.
3. Principles of cancer immunobiology: Immunoediting, surveillance, and
immune escape
The importance of intact immune surveillance in controlling the outgrowth of neoplastic
transformation has been known for decades [10]. With the discovery of the cellular oncogenes,
it became evident that human cancers arise from normal cells and harbor various genetic and
epigenetic alterations, generating potentially recognizable by the immune system cancer
neoantigens [11]. Being of host origin, cancer cells share features of the host. The plastic nature
of tumors makes them adaptive in rebounding from clinical regimens of radiotherapy/
chemotherapy that are traditionally used. The tumor progression can be described as a
continuum of multiple clonal expansions, each of which triggered by the fortunate acquisition
of an enabling mutant genotype. Even when the vast majority of cancer cells are killed by a
cytotoxic chemotherapy drug, a small number of residual cells are primarily or become
secondarily resistant to that agent. They can be sufficient enough to seed the subsequent tumor
regrowth that is resistant to the previously used chemotherapy agent. This leads to the concept
of selection of tumor cells and evolving resistance that becomes a key disease progression
feature; development and progression of cancer is driven by the selection of cells that survive
conditions that are normally lethal. Resistance to any normally lethal condition (radiotherapy,
chemotherapy, etc.) can be selected by the cancer cell population evolution because of the
genetic plasticity, which is an important feature of the cancer cell [12].
The tumor development is a multi-step process, requiring the acquisition of several biological
features: 1) sustained proliferation signaling; 2) evasion of growth suppression; 3) apoptosis
escape; 4) uncontrolled growth and reproduction; 5) angiogenesis induction; and 6) invasion
and metastasizing potential. These hallmarks of the tumor cells ensure their survival, prolif‐
eration, and dissemination [13]. There are other characteristics that facilitate the acquisition of
these hallmarks by the cancer cells, such as the tumor-associated stromal microenvironment
and inflammation, genomic instability, and mutations, mediating the process of tumorigenesis
[14]. There are two more features that are functionally important for the development of cancer
hallmarks. The first feature involves major reprogramming and deregulation of cellular energy
metabolism in order to continuously ensure cell growth and proliferation. The second feature
involves active tumor escape of the immune system destruction and elimination. This
capability highlights the dichotomous role of the immune system that both suppresses and
enhances cancer initiation, promotion, and progression [15-17]. Both of these features may well
prove to facilitate the initiation and progression of many forms of malignant human solid
tumors [14].
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There is a theory suggesting that cells and tissues are constantly monitored by an ever-alert
immune system, and that such immune surveillance is responsible for recognizing and
eliminating the vast majority of incipient cancer cells and thus nascent tumors. According to
this logic, solid tumors that do appear have somehow managed to avoid detection by the
immune system or have been able to limit the extent of immunological killing, thereby escaping
eradication. This is a process called immunoediting—a tumor mechanism, exerting an extrinsic
suppression; it occurs only after a malignant cancerous transformation has already occurred
and the intrinsic tumor suppressor mechanisms have already failed. The cancer immunoedit‐
ing roughly consists of three sequential phases: elimination, equilibrium, and escape. In the
first phase, the body immune system successfully detects cancer cells and eliminates them
efficiently [18,19]. In the equilibrium phase the immune system obstructs tumor growth, but
is unable to completely eradicate the tumor. This step is thought to be continuous in time and
it could either progress to the last escape phase or reverse backwards, leading to complete
tumor eradication by the immune system. If this second phase continues for a longer period
of time, the immune system is incapable of tumor eradication and continuously interacts with
the tumor, thus sculpturing or editing the tumor genetics [20-22]. In the last phase, the tumor
growth is no longer controlled and blocked by the immune system and the tumor spreads and
produces clinically apparent diseases [23].
4. Targets and types of immunotherapy in solid tumors
Immunotherapy is defined as an interaction with the immune system aiming to treat/cure
cancer. Immunotherapy could be largely divided into passive and active.
4.1. Active immunotherapy
Active immunotherapy has recently undergone active clinical research. As tumors express
multiple tumor-associated antigens or neonatigens, the immune system should respond by
adaptive activation of T-lymphocytes against those potential targets as previously described
in section 3.1.2. Any mechanism leading to activation of the immune system is considered as
active immunotherapy. Active immunotherapy has been developed in order to induce and
stimulate the individual’s own immune response. An example of this still-developing branch
of immunotherapy represents Sipuleucel-T, which is the first active cellular immunotherapy
approved for clinical use by the American Food and Drug Agency (FDA) in the treatment of
prostate cancer based on the data that a benefit in survival was observed in the group of
asymptomatic or minimally symptomatic patients with Castrate-resistant prostate cancer
(CRPC) [24]. It consists of autologous peripheral-blood mononuclear cells obtained by
leucopheresis, cultured and activated ex vivo with a recombinant human fusion protein
PA2024 consisting of prostatic acid phosphatase linked to granulocyte-macrophage colony-
stimulating factor (PAP-GM-CSF). GM-CSF stimulates the maturation process of APCs to
mature DCs, while PAP peptides functions with MHC I and II. Upon reinfusion in the patient,
an immune response against PAP-containing cells is triggered [24,25].
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Another example of active immunotherapy is the cellular adoptive immunotherapy using
transfusion of the patient’s own T-lymphocytes previously stimulated ex vivo and currently
tested in phase I/II trials. There is also a wealth of trials with autologous or donor dendritic
cells, autologous tumor cell lysate, activated lymphocytes, or vaccines (DNA, peptide,
recombinant viral vector vaccines, etc.) used as monotherapy or in combination with chemo‐
therapy or other passive immunotherapy options such as anti-CTLA 4 MAB, anti-PD-1 MAB,
and anti-PD-L1 MAB [26-30].
4.2. Passive immunotherapy
At present, passive immunotherapy is still more commonly used as it refers to the delivery of
previously synthesized agents that could be used by the immune system; typical examples are
the use of non-specific immunomodulatory cytokines IFN-α, IL-2, or the specific MAB. Early
clinical studies demonstrated that the use of immunomodulatory cytokines such as interferon
alpha (IFN α) or interleukin 2 (IL-2) may induce antitumor immune-mediated effects as tumor
regression in some solid malignancies [31,32]. Cytokines have been used as cancer immuno‐
therapy for long decades and they work either by exerting a direct antitumor effect or by
indirectly enhancing the antitumor immune response [33]. Multiple in vitro studies have
shown that TNF-α and IL-6 exert direct antitumor effect suppressing cancer cell growth and
survival. However, clinical use of these cytokines in cancer patients has led to less successful
results because of significant toxicity and the controversial influence of a single molecule such
as TNF-α and IL-6. Although they are able to suppress tumor growth, they actually promote
growth of other tumors; further on, IL-6 may also exert immunosuppression. Therefore, the
use of the direct antitumor effect of cytokines remains exclusively an academic pursuit.
In contrast, other cytokines may enhance the antitumor immune response through a variety
of different pathways and thus they are more widely used in the clinical practice. For example,
IL-2 and IFN-α promote T-lymphocytes and NK cells growth and activation, while granulo‐
cyte-macrophage colony-stimulating factor (GM-CSF) acts on APCs, increasing the processes
of antigen processing and presentation as well as the production of co-stimulatory cytokines.
These cytokines are nowadays well-established cancer immunotherapies, e.g., IL-2 is used in
the treatment of metastatic melanoma and metastatic renal cell carcinoma, and IFN-α is
approved for the treatment of malignant melanoma [34,35]. There are reports in the literature
where recombinant IL-2 has also been used in the treatment of other solid tumor malignancies,
including neuroendocrine tumors [36]. This led to the introduction of immunotherapy as an
anticancer treatment for metastatic renal cell carcinoma in 1992 and metastatic melanoma in
1998. Subsequently, immunotherapy with interferon was also approved in the adjuvant setting
in patients with high-risk malignant melanoma as it was considered a beneficial approach
[37,38]. Some other cytokines, such as IL-7, IL-11, IL-12, IL-15, IL-21, IFN-β, and IFN-γ, are also
currently evaluated as cancer immunotherapies.
Another typical example of passive immunotherapy is the use of MAB. There are multiple
MAB used in the treatment of solid malignancies such as the MAB against the Epidermal
Growth Factor (EGFR antibody) cetuximab or the antibody targeting the Human Epidermal
Receptor type 2 (HER 2) trastuzumab. These MAB specifically target their receptor at the cancer
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cell surface and by binding to it, they prevent the signal cascade, transmitted intracellularly,
thus preventing further tumor growth or reproduction. MAB may also target soluble circula‐
tory factors that are important for the tumor such as the MAB bevacizumab, which targets the
vascular endothelial growth factor (VEGF).
MAB may target not only tumor pathways. More recent research focused on the “communi‐
cation” between the host and the tumor, targeting the immune system as a mechanism and
controlling this process. The PD-1/PD-L1 interaction is a major pathway hijacked by tumors
to suppress immune control. The normal function of PD-1 under healthy conditions is to
downmodulate unwanted or excessive immune responses, including autoimmune reactions.
PD-1 is expressed by activated T cells, mediating immunosuppression (Figure 2).
Figure 2. Immunosuppression, mediated via PD-1/PD-L1 pathway. A) PD-1 is expressed by activated T cells; by bind‐
ing to PD-L1, it mediates T-lymphocyte suppression. B) The use of immune checkpoint inhibitors (anti-PD-1 or anti-
PD-L1 MAB) leads to the interruption of this immunosuppression and potential cytotoxicity exerted by the T cells.
PD-1 functions in peripheral tissues where T cells encounter immunosuppressive PD-1 ligands
PD-L1 and PD-L2 that are expressed by tumor cells, stromal cells, or both [39-42]. Inhibition
of the interaction between PD-1 and PD-L1 enhances T cell responses in vitro and mediates
preclinical antitumor activity [39,43]. PD-L1 leads to inhibition of the T-lymphocyte prolifer‐
ation, survival and effector functions (cytotoxicity, cytokine release), inducing apoptosis of
tumor-specific T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells.
The blockade of PD-1/PD-L1 results in a potent and durable tumor regression and prolonged
stabilization in patients with advanced malignancies [44]. Therefore, inhibition of PD-L1
binding to PD-1 represents an attractive strategy to restore tumor-specific T cell immunity.
The mechanism by which PD-1 down modulates T cell responses is similar to, but distinct
from, that of CTLA-4 as both molecules regulate an overlapping set of signaling protein. PD-1
was shown to be expressed on T cells, B cells, monocytes, and natural killer T cells, following
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their activation [45,46]. PD-L1 and PD-L2 are expressed in a variety of cell types, including
non-hematopoietic tissues, as well as in various malignancies. PD-L1 is expressed at low levels
on non-hematopoietic tissues, whereas PD-L2 protein is only detectably expressed on antigen-
presenting cells in lymphoid tissue or chronic inflammatory environments. PD-L2 controls
immune T cell activation in lymphoid organs, whereas PD-L1 serves to protect healthy tissues
from unwarranted T-cell immune-mediated damage.
Although healthy organs express little (if any) PD-L1, many cancers express abundant levels
of this T cell inhibitor. High expression of PD-L1 on tumor cells (and to a lesser extent, PD-L2)
has been found to correlate with poor prognosis and survival in various cancers, including
RCC [47], pancreatic carcinoma [48], hepatocellular carcinoma [49], and ovarian carcinoma
[50]. Furthermore, PD-1 has been suggested to regulate tumor-specific T cell expansion in
melanoma patients [51].
The observed correlation of clinical prognosis with PD-L expression in multiple cancers
suggests that the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion and
should be considered as an attractive target for therapeutic intervention.
Over the past several decades, these observations have resulted in intensive efforts to develop
immunotherapeutic approaches as cancer treatment options. Such agents include immune-
checkpoint-pathway inhibitors such as anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4)
antibody (ipilimumab), anti-programmed death 1 (anti-PD-1) inhibitor (pembrolizumab,
nivolumab, pidilizumab), anti-PD-L1 inhibitors (MPDL3280A, BMS-936559, MEDI4736), etc.
(Table 1).
So far, passive immunotherapy has had limited success in the treatment of solid tumors, except
in the treatment of malignant melanoma and renal cell cancer (RCC) [52-55]. The therapeutic
options for advanced disease in RCC comprise of tyrosine-kinase inhibitors, m-TOR inhibitors,
IL-2, antiangiogenic VEGF inhibitors, and IFNα. Spontaneous remissions and durable
responses have been largely described as a result of this non-specific immune response. The
prognosis of those patients unfortunately remains poor with a 5-year overall survival below
5% [56]. Thus, new options appear on the horizon involving the new specific targeted immu‐
notherapies, focusing on the blockade of T cell regulation and functions, as well as activation
of the dendritic cells (a form of active immunotherapy, described below). There are also phase
I/II trials, studying the potential benefit of cellular adoptive immunotherapy using transfusion
of stimulated patient’s own T-lymphocytes. This adoptive T-lymphocyte therapy consists of
infusion of ex vivo isolated, activated, or expanded tumor-specific T-lymphocytes [57]. There
are different types of adoptive therapy, including TILs, engineered T-cells, expressing a
specific cancer-related receptor (TCRs) or chimeric antigen receptor (CAR). Each of these
approaches has its own advantages and disadvantages.
4.3. Immunotherapy as cancer prevention
Tumor  cells  express  neoantigens  that  are  expressed  as  a  consequence  of  the  malignant
transformation of the host cell. The expression of neoantigens could also be the result of a
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Target Drug name Biologicaldescription
Phase of the trial by tumor site
Phase I Phase II Phase III
CTLA-4
Ipilimumab
(BMS-734016) MAB Pancreatic tumors
Ovarian
Gastric
NSCLC
CRPC
Tremelimumab MAB MEL MEL -
PD-1
Nivolumab
(BMS-936558)
Fully human IgG4
MAB CRPC
Esophageal
carcinoma MEL, NSCLC
Pembrolizumab
Lambrolizumab
(MK-3475)
Humanized IgG4
MAB
CRC, HCC, prostate
cancer RCC, CRC
MEL
NSCLC
RCC
Pidilizumab
(CT-011)
Humanized IgG1
MAB - MEL -
AMP-224 IgG1 fusionprotein Solid malignancies - -
PD-L1
BMS-936559 Fully human IgG4MAB
NSCLC, MEL, CRC,
RCC, ovarian,
pancreatic, breast
cancer
- -
MPDL3280A MAB
NSCLC, MEL, CRC,
ovarian, pancreatic,
breast cancer
RCC, bladder
carcinoma NSCLC
MEDI4736
Medimmune-AZ IgG4 MAB SCCHN MEL NSCLC
This is not an entirely comprehensive list of all trials that have been listed in www.clinicaltrials.com. (Source
www.clinicaltrials.com)
Abbreviations:
CTLA-4: Cytotoxic T-lymphocyte-associated protein 4
PD-1: Programmed death 1
PD-L1: Programmed death 1 ligand
MAB: Monoclonal antibody
MEL: Melanoma
CRPC: Castrate-resistant prostate cancer
RCC: Renal cell carcinoma
NSCLC: Non-small cell lung cancer
CRC: Colorectal cancer
SCCHN: Squamous cell carcinoma of the head and neck
Table 1. Immune-checkpoint-pathway inhibitors and their targets in currently running clinical trials.
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viral or (more rarely) bacterial infection that induced and provoked this malignant transfor‐
mation and thus the idea to vaccinate against those pathogens and prevent the associated
cancer. More than 15% of all cancers are considered to be related to infectious agents [58].
Infection with human papilloma viruses (HPVs) is associated in about 30% of those cases (5%
of all cancers) and hepatitis B and C viruses together with Helicobacter pylori (H. Pylori) account
for 60% more of all infectious-agent-related cancers. It is logical that the success of convention‐
al antimicrobial vaccines could encourage potential cancer vaccine prevention research. This
approach has proven its efficacy in hepatitis B-induced hepatocellular carcinoma [59].  In
carcinoma of the uterine cervix, it is a well-known fact that about 70% of them are caused by
HPV types 16 and 18, and it is expected that HPV-vaccination could decrease the incidence
not only of cervical cancer [60,61], but also of head-and-neck squamous cell carcinoma [62].
The  mechanism,  by  which  HPV induces  malignant  transformation,  is  by  provoking the
synthesis  of  two oncogene  products,  encoded by the  virus,  which  degradate  the  tumor
suppressor protein p53 and block other tumor suppressor proteins cells in the premalig‐
nant  dysplasia  cells,  as  well  as  the  cell  in  the  in  situ  and the invasive carcinomas.  The
recombinant vaccination against HPV leads to secretion of specific antibodies, protecting the
non-infected organisms from HPV-infections,  and the  subsequent  development  of  HPV-
infection-related cancer sites [63]. No significant effect was demonstrated in already HPV-
infected individuals [64].
4.4. Immunotherapy as anticancer treatment
There are 271 trials that are recruiting patients as assessed on 23 Apr 2015 at www.clinicaltri‐
als.com. They include different DNA-vaccines, dendritic cell vaccines, peptide vaccines,
allogeneic GM-CSF-secreting vaccines, recombinant vaccines, vaccines, targeting different
auto-antigens as targets, etc. They are carried in patients with various solid malignancies,
predominantly in melanoma, renal cell carcinoma, non-small cell carcinoma and other solid
tumors. The immunotherapy approach was also implemented in the treatment of neuroendo‐
crine tumors, e.g., vaccination with tumor lysate-pulsed DCs that induced a significant
antitumor immune response in a neuroendocrine carcinoma of the pancreas [65].
A common example of the vaccine’s use as treatment is the Bacillus Calmette-Guerin (BCG),
which represents an attenuated mycobacterium, originally developed as anti-tuberculosis
vaccine. It was only subsequently proven in 1976 that its immunostimulation characteristics
led to antitumor effects in preventing recurrence in patients who underwent transurethral
resection of superficial non-muscle invasive bladder carcinoma and carcinoma in situ when
used as local repeated intravesical instillations [66]. Besides the non-specific immune activa‐
tion, there is a theory suggesting that its anticancer effect might be attributed to specific BCG
internalization in the tumor cells by the integrins and fibronectins of the tumor cells [67,68],
provoking antigen-specific adaptive immune response as well [69-71].
A list of some of the more important clinical trials using cancer vaccines as therapeutic options
are listed in Table 2.
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Vaccine
class
Name and target of
the vaccine Biological description
Phase of the trial by tumor site
Phase I Phase II Phase III
Tumor cell
Pancreatic tumor cell
vaccine
GM-CSF gene-transfected tumor
cell vaccine MEL Pancreas
Algenpantucel-L Allogeneic human pancreaticcancer vaccine RCC, prostate MEL, NSCLC
Pancreas
adenocarcinom
a
SL-701 Multivalent glioma-associatedantigen vaccine - GBM -
DC / APCs
Ovapuldencel-T Autologous PBMCs in GM-CSF -
Ovarian,
peritoneal
carcinoma
-
AGS-003 Autologous DCs transfected withtumor and CD40L RNAs - - RCC
DCVAC/Pca Autologous DCs pulsed withkilled prostate cancer line LNCap - Prostate Prostate
DCVax-L Autologous DCs pulsed withtumor lysate antigen - - GBM
CVac Autologous DCs pulsed withMUC1-mannan fusion protein - Ovarian -
ICT-107 Autologous DCs pulsed withantigens - GBM -
MelCancerVac Autologous DCs pulsed withallogeneic melanoma cell lysate - CRC, NSCLC -
Peptides/
proteins
GV1001 hTERT peptide MEL,pancreatic HCC
NSCLC,
pancreatic
Nelipepimut-S HER2/neu peptide combined withGM-CSF - - Breast
L-BLP25 (Tecemotide) Liposome-encapsulated syntheticpeptide derived from MUC-1 -
Rectal, NSCLC,
prostate, CRC NSCLC
Rindopepimut hEGFR variant III specific peptideconjugated to KLH - GBM GBM
POL-103A Protein antigens from 3 melanomacell lines with alum adjuvant - - MEL
IMA901 Synthetic vaccine consisting of 10different TUMAPs - - RCC
MAGE-A3 MAGE-A3 combined with GM-CSF - Bladder MEL
MAGE-A3 ASCI MAGE-A3 antigen-specific cancerimmunotherapeutic - NSCLC NSCLC
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Vaccine
class
Name and target of
the vaccine Biological description
Phase of the trial by tumor site
Phase I Phase II Phase III
Belange-pumatocel-L Non-viral gene-based allogeneictumor cell vaccine - NSCLC NSCLC
PVX-410 Multi-peptide vaccine - - -
IMA950 Multi-peptide glioma vaccinecontaining TUMAPs GBM GBM -
Racotumumab
Anti-idiotypic vaccine able to
mimic the tumor-associated
antigen NeuGcGM3
- - NSCLC
Genetic
Rilimogene
galvacirepvec
Recombinant fowlpox/vaccinia
virus encoding hPSA and
TRICOM
Prostate Prostate Prostate
CG0070 Oncolytic adenovirus encodingGM-CSF - Bladder -
TG4010
Recombinant modified vaccine
virus strain Ankara, carrying
coding sequences for human
MUC1 antigen and human
interleukin-2 and IL-2
Solid tumors NSCLC NSCLC
Abbreviations:
APC: Antigen-presenting cell
CRC: Colorectal cancer
DC: Dendritic cell
EGFR: Epidermal growth factor receptor
GBM: Glioblastoma
GM-CSF: Granulocyte-macrophage colony-stimulating factor
HCC: Hepatocellular carcinoma
hPSA: Human prostate specific antigen
hTERT: Human telomerase reverse transcriptase
IL-2: Interleukin-2
KLH: Keyhole limpet hemocyanin
MEL: Malignant melanoma
MUC1: Mucin 1
NSCLC: Non-small cell lung cancer
PBMC: Peripheral blood mononuclear cells
RCC: Renal cell carcinoma
TRICOM: Recombinant vaccinia virus vaccine encoding 3 co-stimulatory molecule transgenes B7.1, ICAM-1, and
LFA-3
TUMAPs: Tumor-associated peptides
Table 2. Therapeutic use of cancer vaccines in clinical development in solid malignancies. This is not an entirely
comprehensive list of all trials that have been listed in www.clinicaltrials.com. (Source www.clinicaltrials.com).
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4.5. Predictive and prognostic biomarkers for immunotherapy
Research is ongoing in order to identify potential biomarkers for cancer immunotherapy. In
order to optimize this process, we shall recently be in great demand of predictive/prognostic
factors, justifying the selection of patients, who would be the best candidates for such novel,
expensive, and potentially toxic treatments. PD-L1-positive cancers are associated with poorer
prognoses than PD-1 negative. A correlation of PD-L1 expression and response rate was
demonstrated in patients with the highest levels of PD-L1 expression and PD-L1-positive TILs
[72]. The potential role of PD-L1 as well as TILs as a biomarkers remain to be elucidated.
The presence or absence of TILs also remains to be clarified. There are data that the immune
system plays an important role in the process of recurrence of solid tumors. There is a
multicenter study over 603 patients with colorectal cancer that showed the importance of the
adaptive immune response and the presence/absence of T-lymphocytes in the resected tumor
was a factor that correlated more accurately with clinical outcomes than the current parameters
considered as gold standards for prognosis, histopathologically determined tumor stage (T)
and nodal status (N), yielding a place for TILs as a potential prognostic marker in colorectal
cancer [73] and potentially in other localizations of malignant tumors. It has also been proven
for patients with large early-stage cervical cancer [74], muscle-invasive urothelial bladder
carcinoma [75], and breast cancer [76]. All these findings suggest that assessment and consid‐
eration of the local intratumoral immune response in the primary tumor may have prognostic
value and should be evaluated in the process of treatment decision taking.
5. Adverse effects of immunotherapy
Adverse events (AE) are graded using NCI Common Terminology Criteria for Adverse Events
Version 4.0. Their management is important as the population of treated patients frequently
consists of patients with disseminated disease or patients who have been previously treated
with multiple treatment lines. Most frequent drug-related AEs with potential immune-related
mechanism are hepatitis, pneumonitis, infusion reactions, colitis, arthralgia, and rash,
necessitating sometimes the use of corticosteroids [77]. Fatigue, decreased appetite, nausea,
dyspnea, diarrhea or constipation, vomiting, pyrexia, vitiligo, and headache are also described
as immune-related AEs.
6. Classic chemotherapy and rationale for combination with
immunotherapy
Introduction of immunotherapy into the classic chemotherapy regimens is undoubtedly a
challenge. The use of chemotherapy aims complete direct cancer cell eradication, which
frequently is not achieved. Post chemotherapy exposure to a tumor cell death may be induced,
leading to cancer antigen release. These antigens could be subsequently processed by the APCs
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and the cytotoxic CTLs. Besides a direct cytotoxic effect, such immune modulating effects have
been proven for gemcitabine [78,79]; induction of immunogenic cancer cell death or immune
sensitization for T-lymphocytes killing of the cancer cell has also been described for platinum
compounds [29,80,81]. The effector cells of the immune system seem to remain unaffected [82],
thus suggesting a possible rationale for searching of increased synergistic antitumor activity
by combination of chemotherapy agents and immunotherapy. A large number of clinical trials
are already running in multitude of solid tumor localizations. An example of a combination
with chemotherapeutic agent is the emtansine/trastuzumab complex that is used in the
treatment of HER-2 positive metastatic breast cancer.
Synergistic combinations with immunotherapy are also possible with radiotherapy [83],
targeted agents [84], antiangiogenic drugs, or combining two immunotherapeutic agents with
complementary mechanism of action [85]. There are multiple phase I–III trials, recruiting
patients with solid tumors (MEL, NSCLC, RCC, CRC, etc.) where combinations of two immune
checkpoint inhibitors are used in combination, e.g., anti-CTLA-4 MAB (ipilimumab) with PD-1
or PD-L1 inhibitors. CTLA-4 inhibitors stimulate the T cell activation in lymphatic tissues and
increase the frequency of tumor-specific T cells, while the inhibition of the PD-1/PD-L1 axis
modulates the T cell effector phase in order to overcome T cell anergy present in the tumor
microenvironment [86].
A theory hypothesizes that combining immunotherapy with targeted agents could be syner‐
gistic as targeted agents promote apoptosis in tumor cells, thus enhancing tumor antigen
presentation without adversely effecting immune effector cells; they can also directly modulate
the immune response and improve immune-cell function, essentially acting as immune-
sensitizing agents through different mechanisms [84]. The combination of immunotherapy
with anti-angiogenic agents (e.g., bevacizumab, sunitinib, or pazopanib) is also supported by a
strong biologic rationale as it has been shown that bevacizumab increases the maturation of DCs
and antigen presentation process while sunitinib decreases the number of MDSCs and Tregs
in the tumor microenvironment [87].
The rationale behind combination with radiotherapy is multidimensional, including radiation-
induced tumor cell damage, leading to the spill of tumor-associated antigens, attracting the
immune effector cells [80,88]. Radiotherapy also sensitizes the tumor cells, thus making them
more susceptible to immune-mediated killing; it is partially due to the expression of MHC
class I and death receptors [88]. There is a phase II trial in metastatic malignant melanoma
(NCT01689974), which compares the use of ipilimumab as monotherapy or in combination
with radiotherapy. Another important issue to be addressed in order to optimize the effect of
this strategy is related to the timing of radiotherapy related to the administration of the
immunotherapy [89].
The combination of agents always upfronts the question of antitumor effects and potential
additive toxicity that is largely considered today. Currently, the most frequent combination
remains the administration of immune adjuvants, e.g., IL-2 or GM-CSF with MAB or cancer
vaccines, in order to stimulate the recruitment/activation of immune effector cells.
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7. Tumor response evaluation of immunotherapy
An issue that has been recently recognized is the measurement of antitumor effect of immu‐
notherapy. The cytotoxicity of chemotherapeutic agents often produces a measurable change
in the size of the target lesions within weeks of the initial administration. Response for solid
tumors is most frequently assessed using WHO or RECIST criteria [90,91]. For cytotoxic agents,
these guidelines assume that an early increase in tumor growth and/or appearance of new
lesions signal progressive disease (PD) and the term “progression” became synonymous with
drug failure. Cessation of the currently used chemotherapy is thus recommended once PD has
been detected.
On the other hand, immunotherapeutic agents enhance antitumor immune responses [92] and
achievement of stable disease (SD) may also be viewed as an indicator of meaningful thera‐
peutic effect. Beyond that, additional novel response patterns, observed with these agents,
raise concerns about the interpretation and characterization of WHO or RECIST criteria. In
studies with cytokines, cancer vaccines, and monoclonal antibodies, response classified as CR,
PR, or SD has been shown to occur after an initial increase in tumor burden characterized as
PD by WHO or RECIST criteria [93-96]. Therefore, conventional response criteria may not
adequately assess the activity of immunotherapeutic agents because PD (by initial radio‐
graphic evaluation) does not necessarily reflect therapeutic failure. Thus, in order to system‐
atically characterize additional patterns of response in patients treated with immunotherapy,
underlying WHO criteria were evolved into immune-related response criteria (irRC) [97]. The
core novelty of the irRC is the incorporation of measurable new lesions into “total tumor
burden” and comparison of this variable to baseline measurements (before and after WHO
PD, but not after confirmed irPD). Clinical activity often appears to be delayed following
immunotherapeutic treatment and a period of apparent progression (as defined by the existing
response criteria) may occur, followed by response. Four types of distinct response patterns
have been described (two conventional and two new, unique to immunotherapy): 1) imme‐
diate response; 2) durable stable disease; 3) response after tumor burden increase; and 4)
response in the presence of new lesions. The apparent increase in tumor burden that sometimes
precedes response in patients receiving immune therapy may reflect either continued tumor
growth until a sufficient immune response develops or transient immune-cell infiltration into
the tumor with or without edema [97].
The use of irRC for response evaluation with immunotherapeutic treatment is considered
clinically meaningful as they appear to be related to favorable survival. However, they are still
in early development and prospective trials need to evaluate their role and potential associa‐
tion with survival.
8. Conclusion
A lot of scientific evidence has been recently accumulated over the role of the immune system
in the prevention, development and progression of solid tumors. All this knowledge is
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continuously enriched in order to implicate it into meaningful clinically relevant therapeutic
strategies and use immunotherapy either alone or in combination with other systemic
anticancer treatments. These new strategies will hopefully lead to improvement of the
outcomes of patients with solid malignancies.
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